Korro Bio, Inc. (KRRO) 10-Year Financial Performance & Capital Metrics

KRRO • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutKorro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.Show more

Revenue $2M
EBITDA -$88M -9.2%
Net Income -$84M -3.0%
EPS (Diluted) -9.37 +82.3%
Gross Margin 100%
EBITDA Margin -3890.14%
Operating Margin -4047.12%
Net Margin -3680.36%
ROE -50.61% +77.9%
ROIC -73.92% +60.4%
Debt/Equity 0.28 +42.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.5x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Sales declining 39.9% over 5 years
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-39.89%

3Y-45.55%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-0.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM21.71%

ROCE

10Y Avg-48.59%

5Y Avg-42.28%

3Y Avg-52.37%

Latest-44.46%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	28.95M	36.98M	14.07M	0	0	2.27M
Revenue Growth %	-	-	-	0.28%	-0.62%	-1%	-	-
Cost of Goods Sold+	531K	654K	16.81M	1.58M	3.84M	0	0	0
COGS % of Revenue	-	-	0.58%	0.04%	0.27%	-	-	-
Gross Profit+	-531K	-654K	12.13M	35.4M	10.23M	0	0	2.27M
Gross Margin %	-	-	0.42%	0.96%	0.73%	-	-	1%
Gross Profit Growth %	-	-0.23%	19.55%	1.92%	-0.71%	-1%	-	-
Operating Expenses+	15.78M	18.29M	32.81M	62.95M	94.26M	59M	84.53M	94.18M
OpEx % of Revenue	-	-	1.13%	1.7%	6.7%	-	-	41.47%
Selling, General & Admin	3.99M	6.71M	14.47M	26.3M	34.93M	16.8M	36.54M	30.55M
SG&A % of Revenue	-	-	0.5%	0.71%	2.48%	-	-	13.45%
Research & Development	11.79M	11.58M	18.33M	36.66M	59.32M	42.2M	57.25M	63.64M
R&D % of Revenue	-	-	0.63%	0.99%	4.22%	-	-	28.02%
Other Operating Expenses	0	0	0	0	0	0	-9.25M	0
Operating Income+	-16.31M	-18.94M	-20.68M	-27.55M	-84.03M	-59M	-84.53M	-91.91M
Operating Margin %	-	-	-0.71%	-0.74%	-5.97%	-	-	-40.47%
Operating Income Growth %	-	-0.16%	-0.09%	-0.33%	-2.05%	0.3%	-0.43%	-0.09%
EBITDA+	-15.78M	-18.29M	-19.86M	-25.97M	-80.19M	-56.49M	-80.9M	-88.34M
EBITDA Margin %	-	-	-0.69%	-0.7%	-5.7%	-	-	-38.9%
EBITDA Growth %	-	-0.16%	-0.09%	-0.31%	-2.09%	0.3%	-0.43%	-0.09%
D&A (Non-Cash Add-back)	531K	654K	813K	1.58M	3.84M	2.51M	3.63M	3.56M
EBIT	-20.06M	-19.06M	-18.75M	-26.48M	-83.91M	-59M	-84.53M	-91.91M
Net Interest Income+	0	0	1.78M	994K	-367K	829K	0	0
Interest Income	0	0	1.78M	994K	397K	947K	0	0
Interest Expense	174K	106K	0	0	764K	118K	0	0
Other Income/Expense	-3.93M	-224K	1.93M	1.07M	-640K	976K	3.39M	8.47M
Pretax Income+	-20.24M	-19.17M	-18.75M	-26.48M	-84.67M	-58.02M	-81.14M	-83.44M
Pretax Margin %	-	-	-0.65%	-0.72%	-6.02%	-	-	-36.74%
Income Tax+	0	0	0	35K	15K	10K	27K	141K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-20.24M	-19.17M	-18.75M	-26.51M	-84.69M	-58.03M	-81.17M	-83.58M
Net Margin %	-	-	-0.65%	-0.72%	-6.02%	-	-	-36.8%
Net Income Growth %	-	0.05%	0.02%	-0.41%	-2.19%	0.31%	-0.4%	-0.03%
Net Income (Continuing)	-20.24M	-19.17M	-18.75M	-26.51M	-84.69M	-58.03M	-81.17M	-83.58M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	3.77M	0	0	0	0	0	0
EPS (Diluted)+	-32.27	-30.57	-30.39	-41.10	-4.94	-227.42	-53.08	-9.37
EPS Growth %	-	0.05%	0.01%	-0.35%	0.88%	-45.04%	0.77%	0.82%
EPS (Basic)	-32.27	-30.57	-30.39	-41.10	-4.94	-227.58	-53.09	-9.37
Diluted Shares Outstanding	627.09K	627.09K	616.89K	645.06K	4.45M	255.17K	1.53M	8.92M
Basic Shares Outstanding	627.09K	627.09K	616.89K	645.06K	4.45M	255K	1.53M	8.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.95M	42.94M	221.35M	225.06M	134.75M	57.08M	172.73M	131.53M
Cash & Short-Term Investments	17.94M	42.19M	217.35M	220.34M	130.71M	55.85M	166.15M	126.09M
Cash Only	17.94M	42.19M	200.16M	220.34M	79.64M	36.94M	166.15M	55.64M
Short-Term Investments	0	0	17.2M	0	51.07M	18.91M	0	70.45M
Accounts Receivable	0	161K	805K	340K	144K	0	0	1.7M
Days Sales Outstanding	-	-	10.15	3.36	3.74	-	-	272.58
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	15K	587K	1M	1.83M	1.04M	-376K	3.56M	3.74M
Total Non-Current Assets+	1.83M	1.61M	1.86M	39.66M	50.61M	16.66M	48.94M	94.71M
Property, Plant & Equipment	1.73M	1.51M	1.76M	37.84M	36.87M	11.89M	42.81M	51.55M
Fixed Asset Turnover	-	-	16.43x	0.98x	0.38x	-	-	0.04x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	1.82M	13.42M	4.54M	0	36.96M
Other Non-Current Assets	103K	100K	101K	0	320K	228K	6.12M	6.2M
Total Assets+	19.79M	44.55M	223.22M	264.72M	185.36M	73.74M	221.66M	226.24M
Asset Turnover	-	-	0.13x	0.14x	0.08x	-	-	0.01x
Asset Growth %	-	1.25%	4.01%	0.19%	-0.3%	-0.6%	2.01%	0.02%
Total Current Liabilities+	2.23M	3.77M	52.78M	26.63M	11.43M	8.7M	19.48M	14.96M
Accounts Payable	994K	1.86M	1.22M	5.51M	2.75M	2.6M	7.28M	3.99M
Days Payables Outstanding	683.26	1.04K	26.46	1.27K	261.14	-	-	-
Short-Term Debt	0	0	0	397K	2.58M	2.92M	0	0
Deferred Revenue (Current)	0	0	1000K	1000K	0	0	0	1000K
Other Current Liabilities	479K	876K	3.41M	1.6M	1.73M	551K	395K	4.05M
Current Ratio	8.07x	11.38x	4.19x	8.45x	11.79x	6.56x	8.87x	8.79x
Quick Ratio	8.07x	11.38x	4.19x	8.45x	11.79x	6.56x	8.87x	8.79x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	47.2M	85.28M	3.08M	45.6M	43.1M	164.07M	32.27M	50.87M
Long-Term Debt	46.69M	84.94M	0	15M	14.17M	163.86M	0	0
Capital Lease Obligations	0	0	0	30.6M	28.85M	209K	31.22M	43.48M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	510K	349K	180K	0	87K	0	1.05M	1.47M
Total Liabilities	49.43M	89.06M	55.86M	72.23M	54.53M	172.77M	51.75M	65.83M
Total Debt+	46.69M	84.94M	0	45.99M	45.6M	166.99M	33.21M	44.77M
Net Debt	28.76M	42.75M	-200.16M	-174.35M	-34.04M	130.06M	-132.94M	-10.88M
Debt / Equity	-	-	-	0.24x	0.35x	-	0.20x	0.28x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-93.71x	-178.72x	-	-	-109.99x	-499.98x	-	-
Total Equity+	-29.64M	-44.51M	167.36M	192.49M	130.82M	-99.03M	169.91M	160.41M
Equity Growth %	-	-0.5%	4.76%	0.15%	-0.32%	-1.76%	2.72%	-0.06%
Book Value per Share	-47.27	-70.98	271.29	298.41	29.42	-388.09	111.10	17.98
Total Shareholders' Equity	-29.64M	-48.28M	167.36M	192.49M	130.82M	-99.03M	169.91M	160.41M
Common Stock	13K	14K	31K	34K	35K	0	8K	9K
Retained Earnings	-29.92M	-49.09M	-68.89M	-95.4M	-180.09M	-101.83M	-183M	-266.59M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	54K	27K	-62K	-5K	0	268K
Minority Interest	0	3.77M	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-14.61M	-17.02M	34.22M	-45.19M	-32.09M	-53.65M	-67.28M	-60.07M
Operating CF Margin %	-	-	1.18%	-1.22%	-2.28%	-	-	-26.45%
Operating CF Growth %	-	-0.16%	3.01%	-2.32%	0.29%	-0.67%	-0.25%	0.11%
Net Income	-20.24M	-19.17M	-18.75M	-10.23M	-21.96M	-58.03M	-81.17M	-83.58M
Depreciation & Amortization	531K	654K	813K	1.58M	1.59M	2.51M	3.63M	3.56M
Stock-Based Compensation	0	0	0	0	807K	1.14M	2.38M	4.46M
Deferred Taxes	0	0	0	0	0	-145K	0	0
Other Non-Cash Items	5.88M	1.98M	3.5M	-6.3M	-13.44M	1.51M	3.6M	1.89M
Working Capital Changes	276K	819K	48.65M	-30.24M	904K	-633K	4.28M	13.59M
Change in Receivables	0	0	0	0	0	0	0	-1.7M
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	0	-644K	4.29M	56K	1.75M	3.1M	-1.34M
Cash from Investing+	-1.86M	3.34M	-18.26M	10.4M	-39.5M	11.06M	11.16M	-123.35M
Capital Expenditures	-1.86M	-436K	-1.06M	-6.67M	-4.45M	-5.21M	-7.84M	-17.9M
CapEx % of Revenue	-	-	0.04%	0.18%	0.32%	-	-	7.88%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	13K	0	0	0
Cash from Financing+	27.98M	37.94M	142.01M	56.69M	115.94M	18K	187.76M	69.36M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	-2K	-44K	25.05M	1.97M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.48M	-17.46M	33.15M	-51.86M	-36.54M	-58.86M	-75.12M	-77.98M
FCF Margin %	-	-	1.15%	-1.4%	-2.6%	-	-	-34.34%
FCF Growth %	-	-0.06%	2.9%	-2.56%	0.3%	-0.61%	-0.28%	-0.04%
FCF per Share	-26.28	-27.84	53.74	-80.39	-8.22	-230.65	-49.12	-8.74
FCF Conversion (FCF/Net Income)	0.72x	0.89x	-1.83x	1.70x	0.38x	0.92x	0.83x	0.72x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	11K	27K	141K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-30.52%	-14.73%	-52.39%	-365.06%	-229.04%	-50.61%
Return on Invested Capital (ROIC)	-	-	-	-113.88%	-109.67%	-69.24%	-186.49%	-73.92%
Gross Margin	-	-	41.92%	95.73%	72.7%	-	-	100%
Net Margin	-	-	-64.76%	-71.68%	-601.98%	-	-	-3680.36%
Debt / Equity	-	-	-	0.24x	0.35x	-	0.20x	0.28x
Interest Coverage	-93.71x	-178.72x	-	-	-109.99x	-499.98x	-	-
FCF Conversion	0.72x	0.89x	-1.83x	1.70x	0.38x	0.92x	0.83x	0.72x
Revenue Growth	-	-	-	27.76%	-61.96%	-100%	-	-

Frequently Asked Questions

Growth & Financials

Korro Bio, Inc. (KRRO) reported $7.4M in revenue for fiscal year 2024.

Korro Bio, Inc. (KRRO) grew revenue by 0.0% over the past year. Growth has been modest.

Korro Bio, Inc. (KRRO) reported a net loss of $88.4M for fiscal year 2024.

Dividend & Returns

Korro Bio, Inc. (KRRO) has a return on equity (ROE) of -50.6%. Negative ROE indicates the company is unprofitable.

Korro Bio, Inc. (KRRO) had negative free cash flow of $70.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Korro Bio, Inc. (KRRO) 10-Year Financial Performance & Capital Metrics

KRRO • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $2M
EBITDA -$88M -9.2%
Net Income -$84M -3.0%
EPS (Diluted) -9.37 +82.3%
Gross Margin 100%
EBITDA Margin -3890.14%
Operating Margin -4047.12%
Net Margin -3680.36%
ROE -50.61% +77.9%
ROIC -73.92% +60.4%
Debt/Equity 0.28 +42.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.5x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Sales declining 39.9% over 5 years
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-39.89%

3Y-45.55%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-0.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM21.71%

ROCE

10Y Avg-48.59%

5Y Avg-42.28%

3Y Avg-52.37%

Latest-44.46%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	28.95M	36.98M	14.07M	0	0	2.27M
Revenue Growth %	-	-	-	0.28%	-0.62%	-1%	-	-
Cost of Goods Sold+	531K	654K	16.81M	1.58M	3.84M	0	0	0
COGS % of Revenue	-	-	0.58%	0.04%	0.27%	-	-	-
Gross Profit+	-531K	-654K	12.13M	35.4M	10.23M	0	0	2.27M
Gross Margin %	-	-	0.42%	0.96%	0.73%	-	-	1%
Gross Profit Growth %	-	-0.23%	19.55%	1.92%	-0.71%	-1%	-	-
Operating Expenses+	15.78M	18.29M	32.81M	62.95M	94.26M	59M	84.53M	94.18M
OpEx % of Revenue	-	-	1.13%	1.7%	6.7%	-	-	41.47%
Selling, General & Admin	3.99M	6.71M	14.47M	26.3M	34.93M	16.8M	36.54M	30.55M
SG&A % of Revenue	-	-	0.5%	0.71%	2.48%	-	-	13.45%
Research & Development	11.79M	11.58M	18.33M	36.66M	59.32M	42.2M	57.25M	63.64M
R&D % of Revenue	-	-	0.63%	0.99%	4.22%	-	-	28.02%
Other Operating Expenses	0	0	0	0	0	0	-9.25M	0
Operating Income+	-16.31M	-18.94M	-20.68M	-27.55M	-84.03M	-59M	-84.53M	-91.91M
Operating Margin %	-	-	-0.71%	-0.74%	-5.97%	-	-	-40.47%
Operating Income Growth %	-	-0.16%	-0.09%	-0.33%	-2.05%	0.3%	-0.43%	-0.09%
EBITDA+	-15.78M	-18.29M	-19.86M	-25.97M	-80.19M	-56.49M	-80.9M	-88.34M
EBITDA Margin %	-	-	-0.69%	-0.7%	-5.7%	-	-	-38.9%
EBITDA Growth %	-	-0.16%	-0.09%	-0.31%	-2.09%	0.3%	-0.43%	-0.09%
D&A (Non-Cash Add-back)	531K	654K	813K	1.58M	3.84M	2.51M	3.63M	3.56M
EBIT	-20.06M	-19.06M	-18.75M	-26.48M	-83.91M	-59M	-84.53M	-91.91M
Net Interest Income+	0	0	1.78M	994K	-367K	829K	0	0
Interest Income	0	0	1.78M	994K	397K	947K	0	0
Interest Expense	174K	106K	0	0	764K	118K	0	0
Other Income/Expense	-3.93M	-224K	1.93M	1.07M	-640K	976K	3.39M	8.47M
Pretax Income+	-20.24M	-19.17M	-18.75M	-26.48M	-84.67M	-58.02M	-81.14M	-83.44M
Pretax Margin %	-	-	-0.65%	-0.72%	-6.02%	-	-	-36.74%
Income Tax+	0	0	0	35K	15K	10K	27K	141K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-20.24M	-19.17M	-18.75M	-26.51M	-84.69M	-58.03M	-81.17M	-83.58M
Net Margin %	-	-	-0.65%	-0.72%	-6.02%	-	-	-36.8%
Net Income Growth %	-	0.05%	0.02%	-0.41%	-2.19%	0.31%	-0.4%	-0.03%
Net Income (Continuing)	-20.24M	-19.17M	-18.75M	-26.51M	-84.69M	-58.03M	-81.17M	-83.58M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	3.77M	0	0	0	0	0	0
EPS (Diluted)+	-32.27	-30.57	-30.39	-41.10	-4.94	-227.42	-53.08	-9.37
EPS Growth %	-	0.05%	0.01%	-0.35%	0.88%	-45.04%	0.77%	0.82%
EPS (Basic)	-32.27	-30.57	-30.39	-41.10	-4.94	-227.58	-53.09	-9.37
Diluted Shares Outstanding	627.09K	627.09K	616.89K	645.06K	4.45M	255.17K	1.53M	8.92M
Basic Shares Outstanding	627.09K	627.09K	616.89K	645.06K	4.45M	255K	1.53M	8.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.95M	42.94M	221.35M	225.06M	134.75M	57.08M	172.73M	131.53M
Cash & Short-Term Investments	17.94M	42.19M	217.35M	220.34M	130.71M	55.85M	166.15M	126.09M
Cash Only	17.94M	42.19M	200.16M	220.34M	79.64M	36.94M	166.15M	55.64M
Short-Term Investments	0	0	17.2M	0	51.07M	18.91M	0	70.45M
Accounts Receivable	0	161K	805K	340K	144K	0	0	1.7M
Days Sales Outstanding	-	-	10.15	3.36	3.74	-	-	272.58
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	15K	587K	1M	1.83M	1.04M	-376K	3.56M	3.74M
Total Non-Current Assets+	1.83M	1.61M	1.86M	39.66M	50.61M	16.66M	48.94M	94.71M
Property, Plant & Equipment	1.73M	1.51M	1.76M	37.84M	36.87M	11.89M	42.81M	51.55M
Fixed Asset Turnover	-	-	16.43x	0.98x	0.38x	-	-	0.04x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	1.82M	13.42M	4.54M	0	36.96M
Other Non-Current Assets	103K	100K	101K	0	320K	228K	6.12M	6.2M
Total Assets+	19.79M	44.55M	223.22M	264.72M	185.36M	73.74M	221.66M	226.24M
Asset Turnover	-	-	0.13x	0.14x	0.08x	-	-	0.01x
Asset Growth %	-	1.25%	4.01%	0.19%	-0.3%	-0.6%	2.01%	0.02%
Total Current Liabilities+	2.23M	3.77M	52.78M	26.63M	11.43M	8.7M	19.48M	14.96M
Accounts Payable	994K	1.86M	1.22M	5.51M	2.75M	2.6M	7.28M	3.99M
Days Payables Outstanding	683.26	1.04K	26.46	1.27K	261.14	-	-	-
Short-Term Debt	0	0	0	397K	2.58M	2.92M	0	0
Deferred Revenue (Current)	0	0	1000K	1000K	0	0	0	1000K
Other Current Liabilities	479K	876K	3.41M	1.6M	1.73M	551K	395K	4.05M
Current Ratio	8.07x	11.38x	4.19x	8.45x	11.79x	6.56x	8.87x	8.79x
Quick Ratio	8.07x	11.38x	4.19x	8.45x	11.79x	6.56x	8.87x	8.79x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	47.2M	85.28M	3.08M	45.6M	43.1M	164.07M	32.27M	50.87M
Long-Term Debt	46.69M	84.94M	0	15M	14.17M	163.86M	0	0
Capital Lease Obligations	0	0	0	30.6M	28.85M	209K	31.22M	43.48M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	510K	349K	180K	0	87K	0	1.05M	1.47M
Total Liabilities	49.43M	89.06M	55.86M	72.23M	54.53M	172.77M	51.75M	65.83M
Total Debt+	46.69M	84.94M	0	45.99M	45.6M	166.99M	33.21M	44.77M
Net Debt	28.76M	42.75M	-200.16M	-174.35M	-34.04M	130.06M	-132.94M	-10.88M
Debt / Equity	-	-	-	0.24x	0.35x	-	0.20x	0.28x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-93.71x	-178.72x	-	-	-109.99x	-499.98x	-	-
Total Equity+	-29.64M	-44.51M	167.36M	192.49M	130.82M	-99.03M	169.91M	160.41M
Equity Growth %	-	-0.5%	4.76%	0.15%	-0.32%	-1.76%	2.72%	-0.06%
Book Value per Share	-47.27	-70.98	271.29	298.41	29.42	-388.09	111.10	17.98
Total Shareholders' Equity	-29.64M	-48.28M	167.36M	192.49M	130.82M	-99.03M	169.91M	160.41M
Common Stock	13K	14K	31K	34K	35K	0	8K	9K
Retained Earnings	-29.92M	-49.09M	-68.89M	-95.4M	-180.09M	-101.83M	-183M	-266.59M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	54K	27K	-62K	-5K	0	268K
Minority Interest	0	3.77M	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-14.61M	-17.02M	34.22M	-45.19M	-32.09M	-53.65M	-67.28M	-60.07M
Operating CF Margin %	-	-	1.18%	-1.22%	-2.28%	-	-	-26.45%
Operating CF Growth %	-	-0.16%	3.01%	-2.32%	0.29%	-0.67%	-0.25%	0.11%
Net Income	-20.24M	-19.17M	-18.75M	-10.23M	-21.96M	-58.03M	-81.17M	-83.58M
Depreciation & Amortization	531K	654K	813K	1.58M	1.59M	2.51M	3.63M	3.56M
Stock-Based Compensation	0	0	0	0	807K	1.14M	2.38M	4.46M
Deferred Taxes	0	0	0	0	0	-145K	0	0
Other Non-Cash Items	5.88M	1.98M	3.5M	-6.3M	-13.44M	1.51M	3.6M	1.89M
Working Capital Changes	276K	819K	48.65M	-30.24M	904K	-633K	4.28M	13.59M
Change in Receivables	0	0	0	0	0	0	0	-1.7M
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	0	-644K	4.29M	56K	1.75M	3.1M	-1.34M
Cash from Investing+	-1.86M	3.34M	-18.26M	10.4M	-39.5M	11.06M	11.16M	-123.35M
Capital Expenditures	-1.86M	-436K	-1.06M	-6.67M	-4.45M	-5.21M	-7.84M	-17.9M
CapEx % of Revenue	-	-	0.04%	0.18%	0.32%	-	-	7.88%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	13K	0	0	0
Cash from Financing+	27.98M	37.94M	142.01M	56.69M	115.94M	18K	187.76M	69.36M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	-2K	-44K	25.05M	1.97M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.48M	-17.46M	33.15M	-51.86M	-36.54M	-58.86M	-75.12M	-77.98M
FCF Margin %	-	-	1.15%	-1.4%	-2.6%	-	-	-34.34%
FCF Growth %	-	-0.06%	2.9%	-2.56%	0.3%	-0.61%	-0.28%	-0.04%
FCF per Share	-26.28	-27.84	53.74	-80.39	-8.22	-230.65	-49.12	-8.74
FCF Conversion (FCF/Net Income)	0.72x	0.89x	-1.83x	1.70x	0.38x	0.92x	0.83x	0.72x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	11K	27K	141K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-30.52%	-14.73%	-52.39%	-365.06%	-229.04%	-50.61%
Return on Invested Capital (ROIC)	-	-	-	-113.88%	-109.67%	-69.24%	-186.49%	-73.92%
Gross Margin	-	-	41.92%	95.73%	72.7%	-	-	100%
Net Margin	-	-	-64.76%	-71.68%	-601.98%	-	-	-3680.36%
Debt / Equity	-	-	-	0.24x	0.35x	-	0.20x	0.28x
Interest Coverage	-93.71x	-178.72x	-	-	-109.99x	-499.98x	-	-
FCF Conversion	0.72x	0.89x	-1.83x	1.70x	0.38x	0.92x	0.83x	0.72x
Revenue Growth	-	-	-	27.76%	-61.96%	-100%	-	-

Frequently Asked Questions

Growth & Financials

Korro Bio, Inc. (KRRO) reported $7.4M in revenue for fiscal year 2024.

Korro Bio, Inc. (KRRO) grew revenue by 0.0% over the past year. Growth has been modest.

Korro Bio, Inc. (KRRO) reported a net loss of $88.4M for fiscal year 2024.

Dividend & Returns

Korro Bio, Inc. (KRRO) has a return on equity (ROE) of -50.6%. Negative ROE indicates the company is unprofitable.

Korro Bio, Inc. (KRRO) had negative free cash flow of $70.2M in fiscal year 2024, likely due to heavy capital investments.